The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.

@article{Mallick2008TheHT,
  title={The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.},
  author={Ujjal K Mallick and C. Gerald Harmer and Allan Hackshaw},
  journal={Clinical oncology (Royal College of Radiologists (Great Britain))},
  year={2008},
  volume={20 5},
  pages={325-6}
}
There are about 1600 newly diagnosed patients with thyroid cancer each year in the UK [1] and an estimated 37 000 in the USA [2]. Differentiated thyroid cancer is the most common, with a survival rate of 90% at 10 years. After thyroidectomy, most patients, apart from those at very low risk, are given radioactive iodine to ablate any thyroid remnant, according to the current British Thyroid Association national guidelines [3]. The usual dose given is 3.7 GBq, but for many years there has been… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
8 Extracted Citations
6 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-8 of 8 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-6 of 6 references

Cancer facts and figures 2008

  • C Rubino, F deVathaire, ME Dottorini
  • Guidelines for the management of thyroid cancer…
  • 2007

Manage - ment guidelines for patients with thyroid nodules and differentiated thyroid cancer

  • AK Hackshaw, C Harmer, U Mallick, M Haq, J Franklyn
  • 2006

tiated thyroid cancer. Thyroid 2006;16(2):109e142

  • AK Hackshaw, C Harmer, U Mallick, M Haq, J. Franklyn
  • 2006

Similar Papers

Loading similar papers…